In meta-regression , changes in plasma concentrations of adiponectin , leptin and CRP were associated with duration of treatment , but not with either change in BMI or baseline BMI values .
CONCLUSION Orlistat is effective in increasing plasma concentrations of adiponectin and decreasing those of leptin and CRP
AIMS To conduct a systematic review and meta- analysis of relevant r and omized clinical trials ( RCTs ) to ascertain the effect size of orlistat in modulating plasma levels of adipokines , ghrelin and C-reactive protein ( CRP ) .
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
BACKGROUND The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established . METHODS We enrolled in our study 10,744 overweight or obese subjects , 55 years of age or older , with preexisting cardiovascular disease , type 2 diabetes mellitus , or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events . All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week , single-blind , lead-in period , after which 9804 subjects underwent r and om assignment in a double-blind fashion to sibutramine ( 4906 subjects ) or placebo  ( 4898 subjects ) . The primary end point was the time from r and omization to the first occurrence of a primary outcome event ( nonfatal myocardial infa rct ion , nonfatal stroke , resuscitation after cardiac arrest , or cardiovascular death ) . RESULTS The mean duration of treatment was 3.4 years . The mean weight loss during the lead-in period was 2.6 kg ; after r and omization , the subjects in the sibutramine group achieved and maintained further weight reduction ( mean , 1.7 kg ) . The mean blood pressure decreased in both groups , with greater reductions in the placebo group than in the sibutramine group ( mean difference , 1.2/1.4 mm Hg ) . The risk of a primary outcome event was 11.4 % in the sibutramine group as compared with 10.0 % in the placebo group ( hazard ratio , 1.16 ; 95 % confidence interval [ CI ] , 1.03 to 1.31 ; P=0.02 ) . The rates of nonfatal myocardial infa rct ion and nonfatal stroke were 4.1 % and 2.6 % in the sibutramine group and 3.2 % and 1.9 % in the placebo group , respectively ( hazard ratio for nonfatal myocardial infa rct ion , 1.28 ; 95 % CI , 1.04 to 1.57 ; P=0.02 ; hazard ratio for nonfatal stroke , 1.36 ; 95 % CI , 1.04 to 1.77 ; P=0.03 ) . The rates of cardiovascular death and death from any cause were not increased . CONCLUSIONS Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infa rct ion and nonfatal stroke but not of cardiovascular death or death from any cause . ( Funded by Abbott ; Clinical Trials.gov number , NCT00234832 .
In meta-regression , changes in plasma concentrations of adiponectin , leptin and CRP were associated with duration of treatment , but not with either change in BMI or baseline BMI values .
CONCLUSION Orlistat is effective in increasing plasma concentrations of adiponectin and decreasing those of leptin and CRP
AIMS To conduct a systematic review and meta- analysis of relevant r and omized clinical trials ( RCTs ) to ascertain the effect size of orlistat in modulating plasma levels of adipokines , ghrelin and C-reactive protein ( CRP ) .